GW Pharma Delivers Positive Seizure Data, Worries About Trump
British-based GW Pharmaceuticals (GW) announced positive Phase 3 study results and reported it's year-end earnings results. The company also said that Brexit and the election of Donald Trump in the U.S. could affect its business.
The pharmaceutical company uses cannabidiol (derived from cannabis plants) in its drugs that are used to fight multiple sclerosis and a variety of rare epileptic diseases. The company reported that its revenue fell 64% for 2016 versus 2015, for the year ending Sept. 30. GW's operating loss increased 51%. Overall losses increased 43% year-over-year.
The pharmaceutical company uses cannabidiol (derived from cannabis plants) in its drugs that are used to fight multiple sclerosis and a variety of rare epileptic diseases. The company reported that its revenue fell 64% for 2016 versus 2015, for the year ending Sept. 30. GW's operating loss increased 51%. Overall losses increased 43% year-over-year.